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Primary tumors in cancer are rarely the cause of death for patients as most patients die from metastasis of cancer cells to distant sites of the body. Metastasis is a complex multistep process, during which malignant cells lose contact with the extracellular matrix (ECM) and the neighboring cells within the primary tumor and start invading the surrounding tissues. Thus, integrins and ECM-related adhesion proteins play a crucial role in defining the aggressiveness of cancer cells [1] . In fact, communication between cells and ECM and between the neighboring cells are severely disrupted in more aggressive and invasive cells [1] [2] [3] .
Ras Suppressor-1 (RSU-1), mapped to human chromo some 10, was originally identified to suppress Rasdependent oncogenic transformation, as its name suggests, and it was later shown to be localized to cell-ECM adhesions through its interaction with particularly interesting new cysteine-histidine-rich protein-1 (PINCH-1), an adaptor protein at the cell-ECM adhesion sites known to play an important role in promoting cell survival and apoptosis resistance, while also modulating cell shape and cell spreading (Figure 1 ) [4] [5] [6] [7] [8] .
Interestingly, although RSU-1 was first cloned as early as 1992-1993 and was immediately connected to Ras-dependent oncogenic transformation, which is a fundamental carcinogenesis pathway, little is known regarding its expression and role in cancer [4, 5] . It is clear though, based on the studies currently published on RSU-1 and cancer, that there is consensus on the fact that RSU-1 has anti-tumorigenic effects suppressing cancer cell growth [5, [9] [10] [11] . expression to be dramatically up-regulated in metastatic colon cancer samples compared to healthy controls, as well as compared to primary colon cancer samples [12, 13] .
Furthermore, a somatic copy number variation (CNV) analysis of 98 hepatocellular carcinoma samples showed that the RSU-1 gene exhibited a high frequency of CNVs (9 out of 98 samples) with 7 deletions and 3 amplifications present in the RSU-1 gene, indicating that RSU-1 gene is frequently deleted in human liver cancer [14] .
Moreover, research works on breast cancer showed that RSU-1 expression was significantly elevated both at the mRNA and protein levels in 32 samples from breast cancer patients compared to the respective adjacent normal tissues, with the increase being more obvious in metastatic samples compared to non-metastatic samples [15] .
Moreover, in the same study, RSU-1 was shown to be significantly associated with breast cancer metastasis to the lymph nodes, suggesting a key involvement of RSU-1 in metastatic samples [15] .
Consistent with this finding, RSU-1 was demonstrated to be significantly up-regulated in the aggressive MDA-MB-231 breast cancer cells compared to the less aggres sive MCF-7 cells, as well as in the aggressive HepG2 hepatocellular carcinoma cells compared to the less invasive PLC/ PRF/5 (Alexander) hepatoma cells [15, 16] .
Interestingly, an alternatively-spliced variant of RSU-1 was identified in 30% of high-grade gliomas and twothirds of oligodendrogliomas, but not in other brain, bladder and colon tumors of normal tissues, while rare RSU-1 deletions were also identified in three cancer types from the Cancer Genome Atlas [17, 18] . Hence, RSU-1 seems to have the potential of being both promising and clinically relevant novel marker and therapeutic target for cancer cell metastasis. Current literature findings related to RSU-1 expression in various cancer types are summarized in Table 1 .
Molecular mechanism of RSU-1
The molecular mechanism by which RSU-1 functions inside cells is not as well defined either, with most available information being related to growth inhibition. More specifically, it has been shown that the overexpression of RSU-1 in breast cancer MCF-7 cells leads to the upregulation of cell cycle regulator p21 CIP CDK inhibitor, which explains its growth-suppressor effects [10] .
Moreover, RSU-1 overexpression in response to epidermal growth factor (EGF) stimulation is associated with increased extracellular signal-regulated kinase-2 
Type of lesion Methodology Observation related to RSU-1 References
Colon cancer mRNA expression analysis via realtime PCR RSU-1 up-regulated in metastatic colon cancer samples compared to healthy controls or primary colon cancer samples [13] Hepatocellular carcinoma Gene expression analysis at the protein and mRNA level RSU-1 up-regulated in aggressive HepG2 hepatocellular carcinoma cells compared to the less invasive PLC/PRF/5 (Alexander) hepatoma cells [16] Breast cancer Gene expression analysis at the protein and mRNA level RSU-1 up-regulated in 32 samples from breast cancer patients compared to respective adjacent normal tissues and up-regulated in lymph node-metastatic samples compared to non-metastatic [15] Breast cancer Gene expression analysis at the protein and mRNA level RSU-1 up-regulated in aggressive MDA-MB-231 breast cancer cells compared to less aggressive MCF-7 cells [15] Familial adenomatous polyposis
Comparison of proteomics analysis from primary fibroblast cultures derived from morphologically normal colonic mucosa of familial adenomatous polyposis patients with those obtained from unaffected controls RSU-1 down-regulated in six human polyposis samples compared to six samples from morphologically normal colonic mucosa [12] Hepatocellular carcinoma Somatic copy number variation (CNV) analysis in 98 hepatocellular carcinoma samples RSU-1 gene exhibited a high frequency of CNVs (9 out of 98 samples) with 7 deletions and 3 amplifications present in the RSU-1 gene [14] High-grade gliomas Southern blotting
An alternatively-spliced variant of RSU-1 was identified in 30% of high-grade gliomas and 2/3 of oligodendrogliomas, but not in other brain, bladder and colon tumors of normal tissues [17] Glioblastoma, kidney renal clear cell carcinoma, breast invasive carcinoma
Somatic copy number aberrations analysis
RSU-1 deletions identified in three cancer types from the Cancer Genome Atlas [18] 
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(ERK) kinase activation, decreased activation of Jun kinase and inhibition of Rho kinase (ROCK) activity [10, 19] .
Complementary to the findings of tumor growth inhibition properties of RSU-1, recent work showed that RSU-1 inhibits breast cancer cell proliferation and induces apoptosis by upregulating p53-upregulated-modulator-ofapoptosis (PUMA) [15] . Thus, as far as the inhibition of tumor growth, current literature unanimously confirms that RSU-1 justifies its name and indeed inhibits cell proliferation and tumor growth.
However, other functions of RSU-1 seem more perplexed and less well-defined. For instance, there are two contradictory reports on p38 mitogen-activated protein kinase (MAPK) signaling being regulated by RSU-1; in fact, one report showed that RSU-1 depletion activates p38 signaling, which indicates that RSU-1 is an inhibitor of p38 signaling, while a more recent study indicated that RSU-1 depletion abolishes p38 signaling, making it an activator of p38 [11, 20] . Also, RSU-1 depletion resulted in reduced expression level of PINCH-1, a known binding partner of RSU-1, in one study, and in elevated expression of PINCH-1 in another study [15, 20] . Finally, regarding other cellular functions in which RSU-1 is implicated, there are studies showing that RSU-1 promotes cell adhesion, spreading and migration, and promotes cancer cell invasion, while there is a study showing that RSU-1 inhibits cancer cell migration and invasion [16, 20, 21] .
Taking all the above into account, it seems that the molecular mechanism of RSU-1 action in cancer cells with regard to migration, invasion and metastasis-related properties remains poorly defined. Furthermore, considering the fact that cell-matrix adhesion proteins usually function as adaptor proteins being connected to multiple other cell adhesion proteins and the cytoskeleton with protein-protein interactions to form complex integrin adhesome, it would be of no surprise if RSU-1 was found to form stable interactions with other novel molecules at cell-ECM adhesion sites [22] [23] [24] .
Questions to be addressed
Considering all the above, RSU-1 is clearly related to cancer and seems to be very promising as a potential metastasis biomarker in various types of cancer. However, there are several questions that remain to be addressed with regard to its exact role and molecular mechanism of action. 
